Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.

Scientific reports - 24 Apr 2026

Chen Xuexing, Yan Qiong, Li Chunfang, Liu Fei, Guo Shaojun, Zhao Juan, Liang Yan, Wang Haiyan, Li Weiming, Yuan Guolin

Abstract excerpt

The combination of venetoclax (VEN) and azacitidine (AZA) has transformed the treatment of acute myeloid leukemia (AML) in patients ineligible for intensive therapy. Nevertheless, real-world evidence on long-term outcomes in patients with AML treated with VEN + AZA remains limited. A retrospective analysis was conducted on 79 patients with naïve AML who received at least 6 cycles of VEN + AZA across five...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Nucleophosmin

Share to Sulfonamides

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42032126
DOI: 10.1038/s41598-026-50426-0
PMCID: PMC13280151

Genes

IDH2
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.PMID 42032126Read ↗

Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity Read ↗

Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center studySemantic proximity Read ↗

Efficacy of venetoclax and azacitidine based therapy in favorable-risk unfit acute myeloid leukemia: a real-world studySemantic proximity Read ↗

A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus VenetoclaxSemantic proximity Read ↗

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive ChemotherapySemantic proximity Read ↗

Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Finite-Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia-A Pilot Study.Semantic proximity Read ↗

Safety and efficacy of venetoclax-azacitidine combined with low-dose idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real- world single-center experienceSemantic proximity Read ↗

Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan.Semantic proximity Read ↗

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia NetSemantic proximity Read ↗

Venetoclax combined with hypomethylating agents and the CAG regimen (DCAG) in relapsed/refractory AML: A single- center clinical trialSemantic proximity Read ↗

Homoharringtonine overcomes the negative impact of genetic patterns on venetoclax plus azacitidine regimen in relapsed/refractory acute myeloid leukemia: a multi-center, cohort studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.